Literature DB >> 20200015

Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.

Andreas Tomaschitz1, Stefan Pilz, Eberhard Ritz, Andreas Meinitzer, Bernhard O Boehm, Winfried März.   

Abstract

AIMS: Evidence has accumulated that elevated aldosterone levels are associated with increased risks of fatal cardiovascular (CV) events. With the present analysis, we aimed at evaluating prospectively whether plasma aldosterone correlates with all-cause and CV disease (CVD) mortality in a large cohort of patients. METHODS AND
RESULTS: Median plasma aldosterone concentration (PAC) was 79.0 (48.0-124.0) pg/mL (normal range: 30-160) in 3153 patients [median age: 63.5 (56.3-70.6) years; 30.1% women] who had undergone coronary angiography. After a median follow-up of 7.7 (7.2-8.5) years, a total of 716 participants died [22.7%; 454 (14.4%) due to CV causes and 262 (8.3%) due to non-CV causes]. In multivariable Cox proportional hazard analysis, adjusted for age, gender, antihypertensive treatment, and established CV risk factors, PAC levels stratified in quartiles were significantly associated with all-cause and CVD mortality. Compared with the reference (first) PAC quartile, hazard ratios (confidence interval 95%) for the fourth, third, and second PAC quartiles were 1.30 (1.02-1.65, P = 0.033), 1.32 (1.04-1.68, P = 0.021), and 1.20 (0.93-1.54, P = 0.155) for total mortality and 1.58 (1.15-2.16, P = 0.004), 1.39 (1.01-1.90, P = 0.041), and 1.63 (1.20-2.20, P = 0.002) for CVD mortality, respectively. Analyses for specific causes of CV death revealed strong associations between PAC levels and higher risk for fatal stroke and sudden cardiac death.
CONCLUSION: In a large cohort of patients scheduled for coronary angiography, variation in PAC levels within the normal range is associated with increased all-cause and CVD mortality independent of major established CV risk factors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20200015     DOI: 10.1093/eurheartj/ehq019

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  45 in total

1.  Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease.

Authors:  Alessia Buglioni; Valentina Cannone; Alessandro Cataliotti; S Jeson Sangaralingham; Denise M Heublein; Christopher G Scott; Kent R Bailey; Richard J Rodeheffer; Paolo Dessì-Fulgheri; Riccardo Sarzani; John C Burnett
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

2.  Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study.

Authors:  Anand Vaidya; Bei Sun; Carol Larson; John P Forman; Jonathan S Williams
Journal:  J Clin Endocrinol Metab       Date:  2012-04-26       Impact factor: 5.958

3.  Disentangling the Relationships Between the Renin-Angiotensin-Aldosterone System, Calcium Physiology, and Risk for Kidney Stones.

Authors:  Omar Bayomy; Sarah Zaheer; Jonathan S Williams; Gary Curhan; Anand Vaidya
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

4.  Aldosterone breakthrough during angiotensin receptor blocker use: more questions than answers?

Authors:  Sankar D Navaneethan; Emmanuel L Bravo
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-08       Impact factor: 8.237

5.  Aldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction.

Authors:  Matthew Fomonyuy Yuyun; Sandeep K Jutla; Paulene A Quinn; Leong L Ng
Journal:  Heart Asia       Date:  2012-08-24

6.  Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects.

Authors:  Rene Baudrand; Luminita H Pojoga; Anand Vaidya; Amanda E Garza; Paul A Vöhringer; Xavier Jeunemaitre; Paul N Hopkins; Tham M Yao; Jonathan Williams; Gail K Adler; Gordon H Williams
Journal:  Circulation       Date:  2015-10-02       Impact factor: 29.690

7.  Aldosterone, Renin, Cardiovascular Events, and All-Cause Mortality Among African Americans: The Jackson Heart Study.

Authors:  Joshua J Joseph; Justin B Echouffo-Tcheugui; Rita R Kalyani; Hsin-Chieh Yeh; Alain G Bertoni; Valery S Effoe; Ramon Casanova; Mario Sims; Wen-Chih Wu; Gary S Wand; Adolfo Correa; Sherita H Golden
Journal:  JACC Heart Fail       Date:  2017-08-16       Impact factor: 12.035

8.  Aldosterone impairs coronary adenosine-mediated vasodilation via reduced functional expression of Ca2+-activated K+ channels.

Authors:  Maloree Khan; Alex I Meuth; Scott M Brown; Bysani Chandrasekar; Douglas K Bowles; Shawn B Bender
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-06-14       Impact factor: 4.733

9.  Role and Regulation of MicroRNAs in Aldosterone-Mediated Cardiac Injury and Dysfunction in Male Rats.

Authors:  Jana P Ball; Maryam Syed; Rodrigo O Marañon; Michael E Hall; Roshan Kc; Jane F Reckelhoff; Licy L Yanes Cardozo; Damian G Romero
Journal:  Endocrinology       Date:  2017-06-01       Impact factor: 4.736

10.  Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone.

Authors:  Jenifer M Brown; Jonathan S Williams; James M Luther; Rajesh Garg; Amanda E Garza; Luminita H Pojoga; Daniel T Ruan; Gordon H Williams; Gail K Adler; Anand Vaidya
Journal:  Hypertension       Date:  2013-11-04       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.